Critical Reviews in Oncology / Hematology
Volume 81, Issue 2 , Pages 123-135, February 2012

Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: Inclusion of quality of life and other patient-reported outcomes☆

  • F. Efficace

      Affiliations

    • Italian Group for Adult Hematologic Diseases (GIMEMA), GIMEMA Data Center and Health Outcomes Research Unit, Via Benevento 6, 00161 Rome, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 06 441 639831; fax: +39 06 4402516.
    • ,
  • K. Cocks

      Affiliations

    • University of Leeds, Clinical Trials Research Unit, Leeds, UK
    • ,
  • M. Breccia

      Affiliations

    • University of Rome “Sapienza”, Department of Hematology, Rome, Italy
    • ,
  • M. Sprangers

      Affiliations

    • University of Amsterdam, Academic Medical Center, Department of Medical Psychology, Amsterdam, The Netherlands
    • ,
  • C.A. Meyers

      Affiliations

    • The University of Texas, M.D. Anderson Cancer Center, Department of Neuro-Oncology, Houston, TX, USA
    • ,
  • M. Vignetti

      Affiliations

    • University of Rome “Sapienza”, Department of Hematology, Rome, Italy
    • ,
  • M. Baccarani

      Affiliations

    • University of Bologna, S. Orsola-Malpighi Hospital, Department of Hematology and Oncology, Bologna, Italy
    • ,
  • F. Mandelli

      Affiliations

    • Italian Group for Adult Hematologic Diseases (GIMEMA), GIMEMA Data Center and Health Outcomes Research Unit, Via Benevento 6, 00161 Rome, Italy
    • ,
  • GIMEMA and EORTC Quality of Life Group

Accepted 22 February 2011. published online 25 March 2011.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Presented at the 52nd Annual Meeting of the American Society of Hematology (ASH), December 4–7, 2010, Orlando, FL, USA.

PII: S1040-8428(11)00053-9

doi:10.1016/j.critrevonc.2011.02.007

Critical Reviews in Oncology / Hematology
Volume 81, Issue 2 , Pages 123-135, February 2012

Article Tools

* Image Usage & Resolution